newsfilter
← Latest News
GlobeNewswire·

Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets

SOMERVILLE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (the "Company," "Finch," or "Finch Therapeutics") (NASDAQ:FNCH) today announced its decision to discontinue the PRISM4 Phase 3 trial